Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.

Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S.

JAMA. 2013 Jul 17;310(3):289-96. doi: 10.1001/jama.2013.8638.

PMID:
23860987
2.

Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.

Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI.

Eur Urol. 2014 Dec;66(6):1125-32. doi: 10.1016/j.eururo.2014.01.026. Epub 2014 Jan 28.

PMID:
24495466
3.

Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.

Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S.

Eur Urol. 2011 Dec;60(6):1244-50. doi: 10.1016/j.eururo.2011.08.041. Epub 2011 Aug 27.

PMID:
21908097
4.

Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M.

Eur Urol. 2015 Sep;68(3):386-96. doi: 10.1016/j.eururo.2014.11.039. Epub 2014 Dec 5. Review.

5.

Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.

Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, Loeb S, Nguyen PL, Trinh QD.

JAMA Oncol. 2016 Apr;2(4):500-7. doi: 10.1001/jamaoncol.2015.4917.

PMID:
26720632
6.

Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.

Martín-Merino E, Johansson S, Morris T, García Rodríguez LA.

Drug Saf. 2011 Nov 1;34(11):1061-77. doi: 10.2165/11594540-000000000-00000.

PMID:
21981434
7.

Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.

Wu CT, Yang YH, Chen PC, Chen MF, Chen WC.

Osteoporos Int. 2015 Sep;26(9):2281-90. doi: 10.1007/s00198-015-3135-9. Epub 2015 May 20.

PMID:
25990353
8.

Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.

Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL.

Eur Urol. 2012 Jun;61(6):1119-28. doi: 10.1016/j.eururo.2012.01.045. Epub 2012 Feb 1.

9.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23.

10.

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.

Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM.

J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7. Epub 2005 Sep 27.

PMID:
16189261
11.

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.

Cochrane Database Syst Rev. 2014 Jun 30;(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Review.

PMID:
24979481
12.

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK.

JAMA. 2011 Dec 7;306(21):2359-66. doi: 10.1001/jama.2011.1745.

PMID:
22147380
13.

Androgen deprivation and thromboembolic events in men with prostate cancer.

Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, Scardino PT, Eastham JA, Elkin EB.

Cancer. 2012 Jul 1;118(13):3397-406. doi: 10.1002/cncr.26623. Epub 2011 Nov 9.

14.

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, Montorsi F, Karakiewicz PI.

BJU Int. 2014 Dec;114(6b):E82-E89. doi: 10.1111/bju.12732. Epub 2014 Jul 27.

15.

Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.

O'Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, Van Hemelrijck M.

BJU Int. 2016 Sep;118(3):391-8. doi: 10.1111/bju.13360. Epub 2015 Nov 19.

PMID:
26497726
16.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

17.

ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.

Crawford ED, Moul JW.

Oncology (Williston Park). 2015 Jan;29(1):55-8, 65-6. Review.

18.

Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.

Wang A, Obertová Z, Brown C, Karunasinghe N, Bishop K, Ferguson L, Lawrenson R.

BMC Cancer. 2015 Nov 2;15:837. doi: 10.1186/s12885-015-1843-3.

19.

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU.

N Engl J Med. 2011 Jul 14;365(2):107-18. doi: 10.1056/NEJMoa1012348.

20.

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.

Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.

Int J Cancer. 2016 Dec 15;139(12):2698-2704. doi: 10.1002/ijc.30403. Epub 2016 Sep 19.

Supplemental Content

Support Center